An updated integrated analysis of patients (n = 3492) with moderately to severely active rheumatoid arthritis (RA), including patients exposed to any dose of baricitinib for up to 5.5 years, showed that the safety profile of baricitinib was maintained as similar to that previously reported.
Suboptimal EHR Reporting of Clinical Measures in RA Patients Receiving a Biologic or Targeted Synthetic DMARD
A real-world analysis of electronic health record (EHR) databases across Integrated Delivery Networks showed lower EHR reporting rates of clinical and disease severity measures, thus compromising the ability of rheumatologists to adopt a guideline-recommended treat-to-target approach in clinical practice.
Both Tofacitinib and Baricitinib in Combination with Methotrexate Are Efficacious in Patients with RA
Results from a systematic review and network meta-analysis of randomized controlled trials showed that tofacitinib 10 mg and baricitinib 8 mg combined with methotrexate were both effective in patients with rheumatoid arthritis (RA), with similar safety outcomes.
No Increased Cardiovascular Risk in Patients with RA Who Newly Initiated Tocilizumab versus Abatacept
A large multidatabase, population-representative cohort study showed a similar risk for primary composite cardiovascular events between patients with rheumatoid arthritis (RA) who newly started tocilizumab and abatacept starters.
Long-Term Efficacy and Safety with Ibrutinib in Previously Treated CLL: Up to 4 Years’ Follow-Up of the RESONATE Study
This 4-year follow-up of the phase 3 RESONATE study provides updated data on the efficacy and safety of ibrutinib, comparing the long-term efficacy and safety of ibrutinib versus ofatumumab in patients with chronic lymphocytic leukemia (CLL).
Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
GENUINE, the first randomized phase 3 trial conducted to assess the addition of a novel agent, ublituximab, to ibrutinib in high-risk, relapsed/refractory chronic lymphocytic leukemia (CLL), evaluates ibrutinib monotherapy versus ublituximab and ibrutinib.
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
Page 2 of 8
Results 11 - 20 of 76
Results 11 - 20 of 76